Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Craig B.H. Surman, M.D.

Co-Author

This page shows the publications co-authored by Craig Surman and Robert Doyle.
Connection Strength

0.403
  1. Surman CB, Hammerness PG, Petty C, Spencer T, Doyle R, Napolean S, Chu N, Yorks D, Biederman J. A pilot open label prospective study of memantine monotherapy in adults with ADHD. World J Biol Psychiatry. 2013 May; 14(4):291-8.
    View in: PubMed
    Score: 0.136
  2. Surman C, Hammerness P, Petty C, Doyle R, Chu N, Gebhard N, Williams C, Biederman J. Atomoxetine in the treatment of adults with subthreshold and/or late onset attention-deficit hyperactivity disorder-not otherwise specified (ADHD-NOS): a prospective open-label 6-week study. CNS Neurosci Ther. 2010; 16(1):6-12.
    View in: PubMed
    Score: 0.117
  3. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Kotarski M, Spencer T. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2010 Oct; 30(5):549-53.
    View in: PubMed
    Score: 0.031
  4. Spencer TJ, Mick E, Surman CB, Hammerness P, Doyle R, Aleardi M, Kotarski M, Williams CG, Biederman J. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. J Atten Disord. 2011 May; 15(4):286-94.
    View in: PubMed
    Score: 0.030
  5. Biederman J, Mick EO, Surman C, Doyle R, Hammerness P, Michel E, Martin J, Spencer TJ. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry. 2007 Sep 14; 7:49.
    View in: PubMed
    Score: 0.025
  6. Biederman J, Mick E, Spencer T, Surman C, Hammerness P, Doyle R, Dougherty M, Aleardi M, Schweitzer K. An open-label trial of OROS methylphenidate in adults with late-onset ADHD. CNS Spectr. 2006 May; 11(5):390-6.
    View in: PubMed
    Score: 0.023
  7. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006 May 01; 59(9):829-35.
    View in: PubMed
    Score: 0.022
  8. Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, Mick E, Aleardi M, Herzig K, Faraone S. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Mar 01; 57(5):456-63.
    View in: PubMed
    Score: 0.021
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.